CION Ameerpet
Ovarian cancer can begin in one ovary or involve both, and in the commonest type it involves both more often than not. Both ovaries being affected is not the same as the cancer being advanced. Where the disease is still confined to the ovaries, involving two rather than one moves the stage from IA to IB — both of which are Stage I.
It can do either, and which it does depends almost entirely on the type of ovarian cancer. People who search ovarian cancer both ovaries are usually asking one of two things: my scan mentions both sides — is that worse?, or only one ovary is affected — will the other one be taken too? Both deserve a straight answer, and the answers are different.
In high-grade serous carcinoma — the commonest ovarian cancer by a wide margin — both ovaries are involved in a large share of cases at the time of diagnosis. That is not bad luck, and it is not a sign of delay. It is how that disease behaves. There is good evidence that many high-grade serous cancers begin in the fimbrial end of a fallopian tube, close to the ovary, and that cells shed from there settle on the ovarian surfaces and the lining of the abdomen. When both ovaries are involved, they are usually two landing sites for one disease rather than two separate cancers. Our guide to high-grade serous ovarian carcinoma explains that subtype in full.
This is why the term bilateral ovarian cancer describes an anatomical finding and not a severity. Staging measures how far the disease has travelled from the ovaries — into the pelvis, across the abdomen, into lymph nodes, or beyond. It does not add points for a second ovary. Disease sitting in both ovaries and nowhere else is still early-stage disease.
In the commonest subtype, involvement of both ovaries is the expected pattern rather than the exception. It reflects how the disease spreads, not how long it was left.
Disease confined to one ovary is FIGO Stage IA. Disease confined to both is Stage IB. Both are Stage I — the disease has not left the ovaries in either case.
Whether one ovary or two are involved has the biggest effect on how much is removed, on fertility-sparing options, and on whether menopause starts at once.
Under the FIGO staging system for cancer of the ovary, fallopian tube and peritoneum, tumour limited to one ovary or tube — capsule intact, no tumour on the surface, negative washings — is Stage IA. Exactly the same picture in both ovaries or tubes is Stage IB. Both sit inside Stage I, the category for disease that has not spread beyond the ovaries and tubes. In other words, the staging system treats a second involved ovary as a detail of extent within Stage I, not as a jump to a later stage. Source: Prat J, FIGO Committee on Gynecologic Oncology, International Journal of Gynecology & Obstetrics (2014); NCCN Ovarian Cancer guidelines.
Laterality is one of the first things a pathologist and a gynaecologic oncologist read, because each subtype has a characteristic pattern. Here is what one ovary or two typically means for each.
This is the commonest ovarian cancer and the one most likely to involve both ovaries at diagnosis. Much of it is now believed to originate in the fimbrial end of the fallopian tube, where a precursor lesion called serous tubal intraepithelial carcinoma can be found in surgically removed tubes. Cells shed into the pelvic fluid then implant on whichever surfaces they reach — commonly both ovaries, the peritoneum and the omentum.
Because of that mechanism, both tubes and both ovaries are removed as part of standard surgery for this subtype, even when a scan suggested one side was normal. The apparently normal side often turns out to carry microscopic disease that imaging could not show.
Low-grade serous carcinoma is far less common than the high-grade form, tends to affect younger women, and grows slowly. It involves both ovaries in a meaningful proportion of cases, though less consistently than high-grade serous disease.
Serous borderline tumours — which are not frankly malignant and carry a very different outlook — are also bilateral in a substantial minority of women. Because they often occur before menopause, laterality here has direct consequences for fertility planning. That is a conversation to have before surgery rather than after it.
A primary mucinous ovarian cancer is characteristically one-sided, and often large by the time it is found. When a mucinous tumour appears in both ovaries, pathologists treat that as a signal that the ovaries may not be where the cancer started.
Mucinous cancers of the stomach, bowel, appendix and pancreas can spread to both ovaries and closely imitate a primary ovarian tumour. Telling the two apart matters enormously, because treatment follows the organ of origin. This is one situation where bilateral involvement genuinely changes the work-up, prompting endoscopy, colonoscopy or a careful look at the appendix alongside immunohistochemistry on the specimen.
Both of these subtypes are more often confined to a single ovary, and both are associated with long-standing endometriosis. Endometriosis itself frequently affects both ovaries, so a woman can have an endometrioma on one side and a cancer arising within an endometrioma on the other.
Endometrioid ovarian cancer also has a well-recognised habit of appearing alongside a separate cancer of the uterine lining. That is why the uterus is assessed carefully rather than assumed to be innocent, and why the pathology report tells you more than the scan did.
Germ cell tumours are the ovarian cancers of adolescence and early adulthood. The great majority are confined to one ovary, which is precisely why fertility-sparing surgery is so often possible in this group, and why the outlook is generally good even when the tumour is large.
The exception is dysgerminoma, which involves the opposite ovary in a minority of cases and therefore warrants careful assessment of both sides at operation. If you are being counselled about surgery at a young age, ask specifically about removing only the affected ovary and tube — for many germ cell tumours it is a standard option, not a special request.
Granulosa cell tumours and the other sex cord-stromal tumours are typically one-sided. They often declare themselves through hormonal effects — irregular or heavy bleeding, bleeding after menopause, or in rarer androgen-producing tumours a deepening voice and unwanted hair growth — rather than through the bloating and pressure symptoms of epithelial cancer.
Because they are usually unilateral and often found early, conserving the other ovary can be reasonable in younger women. That decision belongs to a gynaecologic oncologist who has seen the imaging and the pathology, not to a general rule read online.
Not every cancer found in the ovaries began there. Stomach, bowel, appendix, breast and endometrial cancers can all spread to the ovaries, and when they do they characteristically involve both. The classical example is the Krukenberg tumour, most often from a stomach primary, which typically presents as bilateral solid ovarian masses.
This possibility is a real reason to mention any previous cancer, however long ago and however well treated, when bilateral ovarian masses are found. It changes which tests are done next and, if confirmed, changes the whole treatment plan — because the disease is then treated as the cancer it actually is.
Findings on both sides are common and usually benign. Polycystic ovaries are bilateral by definition and are not tumours; functional cysts, endometriomas and dermoids all frequently affect both ovaries. These are the features that move a bilateral finding from routine to worth a specialist opinion.
Simple, thin-walled, fluid-filled cysts on both sides are reassuring. Solid areas, thick internal walls, nodules projecting into the cyst or brisk blood flow are what prompt a closer look.
New ovarian masses on both sides after the periods have stopped carry more weight than the same finding at 30, because the ordinary hormonal explanations no longer apply.
Ascites alongside bilateral ovarian masses is the combination that should not be watched and rescanned in six months. It needs prompt assessment.
Bilateral ovarian masses in someone treated for stomach, bowel, appendix or breast cancer raise the possibility of spread to the ovaries, which is investigated differently.
A bilateral finding that is larger and more solid than it was three months ago is behaving in a way that benign cysts usually do not.
Any ovarian finding warrants a lower threshold for specialist review here. Note also that there is no effective screening test for ovarian cancer, in BRCA carriers or in anyone else.
None of these means you have cancer, and most women with bilateral findings do not have it. They are reasons to have the scan reviewed by someone who reads ovarian imaging every week, rather than to wait and see. Start with the complete ovarian cancer guide if you want the wider picture first.
Bring the ultrasound, the CT report or the histopathology. In 45 minutes a specialist can tell you what one ovary or two actually means for stage, for surgery, and for the choices you still have.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
The first consultation is free and runs to 45 minutes. No referral needed, and nothing quoted at you without the context that makes sense of it.
The honest summary: laterality reshapes the operation and the fertility conversation, and barely touches the things people fear it decides.
| Question | One ovary involved | Both ovaries involved |
|---|---|---|
| FIGO stage, disease confined to the ovaries | Stage IA. | Stage IB — still Stage I, still confined to the ovaries. |
| Standard surgery | Removal of the affected ovary and tube, with full surgical staging. | Removal of both ovaries and both tubes, with full surgical staging. |
| Conceiving later with your own eggs | May remain possible in selected early, favourable cases, particularly germ cell tumours. | Not usually possible. Preserving the uterus for a future donor-egg pregnancy is sometimes discussed. |
| Menopause | Usually not immediate — the remaining ovary keeps producing hormones. | Immediate surgical menopause if you have not already been through it, with support planned in advance. |
| Whether chemotherapy is advised | Decided by subtype, grade and stage. | Decided by the same three things. A second involved ovary is not, by itself, the trigger. |
| What it says about outlook | Depends on stage, subtype, grade, and how completely surgery clears the disease. | The same factors. Disease in both ovaries is not the same as disease that has spread beyond them. |
*Stage is confirmed by the pathologist after surgery, not by the scan. All ovarian cancer surgery — staging surgery, removal of one or both ovaries, debulking and fertility-sparing surgery — is coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there.
A report that says bilateral adnexal masses is one of the most alarming things a person can read with no explanation attached to it. Most of the time it describes something benign. When it does not, the number of ovaries involved matters far less than the subtype, the grade, and whether the disease has stayed inside the ovaries — and none of that can be settled from the scan alone.
Your first consultation at CION is free and runs to about 45 minutes. That is long enough to go through the imaging line by line, take a proper family history, and decide what testing is genuinely warranted rather than ordering a panel. Cases that raise a question are discussed at a tumour board rather than decided by one doctor.
Where a cancer is confirmed, CION delivers medical oncology in-house: platinum-based chemotherapy and PARP-inhibitor-class maintenance therapy across 35+ centres in Telangana and Andhra Pradesh, together with genetic counselling, BRCA and HRD testing, nutrition support, and survivorship follow-up that includes menopause care after both ovaries are removed. Surgery is different, and we say so plainly. Staging surgery, oophorectomy, debulking and fertility-sparing procedures are coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there. Our ovarian cancer treatment in Hyderabad page sets out how the whole pathway fits together.
Free, unhurried and with a specialist. Long enough to read the report with you and explain what bilateral involvement does and does not mean.
Medical oncology, imaging and pathology review the case together, which matters most when the question is where a bilateral tumour actually started.
Genetic counselling with BRCA and HRD testing, and cascade testing for family members, delivered at CION rather than referred out.
Ovarian surgery is performed by specialist gynaecologic-oncology surgeons at partner centres and may be billed there. You hear that from us upfront.
Both patterns are common, and the type decides which. High-grade serous carcinoma, which accounts for most ovarian cancers, involves both ovaries in a large share of cases at diagnosis, because it often begins in the fallopian tube and seeds both ovarian surfaces. Mucinous, endometrioid, clear cell and most sex cord-stromal tumours are usually confined to one ovary. Germ cell tumours in young women are almost always one-sided, with dysgerminoma the exception. So a report describing both ovaries is not unusual, and it does not mean the cancer was caught late. It mainly tells the surgical team what the operation needs to cover.
Almost certainly not. Findings on both ovaries are extremely common and the great majority are benign. Polycystic ovaries are bilateral by definition and are not tumours at all. Functional cysts follow the menstrual cycle and often appear on both sides. Endometriomas and dermoid cysts are each bilateral in a meaningful minority of women. What a specialist looks at is the character of what is there, not the number of ovaries: simple, thin-walled, fluid-filled cysts are reassuring, while solid areas, thick internal walls, nodules or free fluid in the abdomen are the features that prompt further imaging and a specialist opinion. Your age and menopausal status weigh into that judgement too.
No, and this is the most common misunderstanding about bilateral ovarian cancer. The FIGO staging system measures how far disease has travelled away from the ovaries and tubes, not how many ovaries contain it. Tumour confined to one ovary is Stage IA, tumour confined to both is Stage IB, and both sit within Stage I, the category for disease that has not spread beyond the ovaries and tubes. Stage rises when disease extends into the pelvis, across the abdominal cavity, into lymph nodes, or to distant organs. A second involved ovary is a detail of extent inside Stage I, not a jump to a later stage.
Sometimes, and it is worth asking before surgery rather than after. Fertility-sparing surgery, which removes only the affected ovary and tube and leaves the other ovary and the uterus in place, is a recognised option in carefully selected cases: early-stage disease genuinely confined to one side, a favourable subtype and grade, and a full staging operation confirming nothing else is involved. It is most often possible with germ cell tumours, and with some borderline and low-grade tumours in younger women. It is generally not appropriate in high-grade serous carcinoma, where both tubes and ovaries are removed as standard. This surgery is coordinated with specialist gynaecologic-oncology surgeons at partner centres.
If you have not already been through menopause, removing both ovaries brings it on immediately rather than gradually, and the symptoms can be more abrupt than a natural menopause: hot flushes, disturbed sleep, mood changes, vaginal dryness. Longer term, bone and cardiovascular health need attention. None of this should come as a surprise on the day of discharge. Ask before surgery what support is planned, including whether hormone replacement is appropriate for you, which depends on your subtype and the rest of your treatment and is an individual decision made with your treating team. At CION, menopause care and survivorship follow-up are part of routine in-house follow-up rather than an afterthought.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house, which covers platinum-based chemotherapy and PARP-inhibitor-class maintenance therapy across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling, BRCA and HRD testing, nutrition support and survivorship follow-up. Ovarian surgery is different, and we say so plainly: staging surgery, removal of one or both ovaries, debulking and fertility-sparing procedures are coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there. Every case that raises a question is reviewed at a tumour board rather than decided by a single doctor.